Clinical trials: Non Metastatic Cancer
Non-small Cell Lung Cancer
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the effect on toxicity of the addition of CS 1008 to a platinum based chemotherapy regimen on the progression-free survival (PFS) in subjects with stage IIIB wet or stage IV NSCLC.
- Trial name
- NCT00991796
- Testing
- CS-1008, Paclitaxel, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Daiichi Sankyo
Urethral Neoplasms, Neoplasms, Urethral
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Background: Gemcitabine and carboplatin are chemotherapy drugs used to treat several types of cancer, including cancer of the pancreas, bladder, ovaries, and lung.
- Conditions
- Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
- Trial name
- NCT01352962
- Testing
- Gemcitabine, Carboplatin, Lenalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
Patients with metastatic non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) expression below 50% are commonly treated with different chemo-immunotherapy regimens in routine clinical practice.
- Trial name
- ALCG-01 (NCT07394062)
- Testing
- Pembrolizumab, Nivolumab, Ipilimumab (1mg/kg)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 400 people
- Sponsor
- Gazi University
Nasopharyngeal Carcinoma (NPC)
A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma
Proton therapy for nasopharyngeal carcinoma can reduce radiotherapy-related toxic reactions, and some retrospective studies have found that proton therapy improves the survival of patients with nasopharyngeal carcinoma.
- Trial name
- NCT07578727
- Testing
- Proton Therapy System (ProBeam), Photon Therapy System (TrueBeam)
- Where
- 2 sites in China
- Volunteers
- 504 people
- Sponsor
- Guangzhou Concord Cancer Center
Lymphoma, Small Intestine Cancer
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031941
- Testing
- lenalidomide
- Where
- 2 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
This study is carried out to see how Caucasian patients with lung cancer which has EGFR mutation will respond to gefitinib (IRESSA™) as a first line treatment.
- Trial name
- IFUM (NCT01203917)
- Testing
- Gefitinib
- Where
- 61 sites in Bulgaria, France and 11 more
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain…
- Conditions
- MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis
- Trial name
- NCT06582940
- Testing
- MRI-guided adaptive SRT, Conventional SRT
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 10 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Non-small Cell Lung Cancer
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-small cell lung cancer by…
- Trial name
- NCT04345146
- Testing
- FSRT combined with Bevacizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in…
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
- Trial name
- NCT05607550
- Testing
- furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 398 people
- Sponsor
- ArriVent BioPharma, Inc.
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Background: Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein.
- Conditions
- Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS
- Trial name
- NCT00242723
- Where
- United States
- Volunteers
- 1,559 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Non-small Cell Lung Cancer
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 for injection in combination with glecirasib in the treatment of patients with locally advanced or metastatic non-small cell lung cancer with…
- Trial name
- NCT07827261
- Testing
- BL-B01D1, Glecirasib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
This randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread to nearby tissue or lymph nodes (locally advanced), that cannot…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT02849496
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 58 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab…
- Trial name
- NCT07098988
- Testing
- Visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2
- Where
- 51 sites in United States, Germany and 5 more
- Volunteers
- 107 people
- Sponsor
- CatalYm GmbH
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
Background: In European Association of Urology (EAU) Guidelines, the vast majority of non-muscle-invasive bladder cancers (NMIBCs) undergo a primary transurethral resection of the bladder tumor (TURBT) followed by a repeat TURBT…
- Conditions
- Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- CUT-less (NCT05962541)
- Testing
- PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM)
- Where
- Italy
- Volunteers
- 327 people
- Sponsor
- University of Roma La Sapienza
Carcinoma, Non-Small-Cell Lung
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
Protocol AMP-024 is a Phase 2 study of imexon plus docetaxel for patients with previously treated lung cancer that has spread in the body.
- Trial name
- NCT00697060
- Testing
- Imexon + docetaxel
- Where
- 3 sites in United States
- Sponsor
- AmpliMed Corporation
Metastatic Colorectal Cancer
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection.
- Trial name
- NCT05103020
- Testing
- intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks, IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University